A Case of Bone, Lung, Pleural and Liver Metastases from Renal Cell Carcinoma Which Responded Remarkably Well to Zoledronic Acid Monotherapy
Overview
Affiliations
Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC). Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer. The patient in the present report had multiple bone metastases from RCC. Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks. Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment. The metastases have shown no progression for 20 months since starting the ZA treatment. We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.
Wang Z, Xu C, Liu W, Zhang M, Zou J, Shao M Front Endocrinol (Lausanne). 2023; 13:1083569.
PMID: 36686417 PMC: 9850289. DOI: 10.3389/fendo.2022.1083569.
Riddle M, Lockhart A, Sorscher S World J Oncol. 2017; 1(5):208-209.
PMID: 29147208 PMC: 5649799. DOI: 10.4021/wjon244w.
Aapro M, Saad F Ther Adv Urol. 2012; 4(2):85-101.
PMID: 22496711 PMC: 3317544. DOI: 10.1177/1756287212441234.
Immunologic mechanisms in RCC and allogeneic renal transplant rejection.
Bedke J, Stenzl A Nat Rev Urol. 2010; 7(6):339-47.
PMID: 20458329 DOI: 10.1038/nrurol.2010.59.